On Track Innovations Ltd (USA) (NASDAQ:OTIV) swung to a lower-than-expected net loss in Q3 with revenues that were just shy of the Street consensus. The provider of near field communication (NFC) and cashless payment solutions cut its full-year outlook on revenue growth citing the short-term impact deriving from the recent launch of Apple's (AAPL) NFC payment service Apple Pay. Q3 net loss from continuing operations totaled $2.3 million or $0.07 per share compared to net income of $2.6 million, or $0.08 per share in the year-ago period, beating the Street forecast of a loss of $0.08 per share.Quarterly revenues fell 4% year-on-year to $5.3 million, below the consensus of $5.5 million due to lower petroleum segment revenues and a delay in NFC reader sales. On Track Innovations Ltd (USA) (NASDAQ:OTIV) CEO Ofer Tziperman said the impact of "Apple's adoption of NFC is extraordinarily favorable to our growth and profitability," yet cautioned that the "short-term impact requires us to adjust our expectations for fiscal 2014," as various customers delayed their purchases in recent months due to "uncertainties over compatibility with Apple Pay." The company said it expects revenue growth of 10% in 2014, down from a previous outlook of at least 30% revenue growth. OTIV closed lower at $2.60 on Monday, in a 52-week range of $1.73 - $5.00.Click here for a free comprehensive Trend Analysis ReportSabre Corp (NASDAQ:SABR) reported Q3 adjusted earnings in-line with Street estimates with quarterly revenues below the consensus of analysts polled by Capital IQ. Q3 adjusted net income from continuing operations totaled $69.9 million, or $0.26 per share, compared to net income of $51.7 million, or $0.28 per share in the year-ago period. Analysts were expecting earnings of $0.26 per share. Revenues fell to $756 million from $776 million, below the consensus of $781.5 million.The technology provider to the travel and tourism industry sees full-year revenues of $2.76 billion - $2.79 billion with adjusted earnings expected between $0.90 and $0.96 per share. The guidance excludes lastminute.com and is not comparable to the previous outlook, the company noted. Sabre Corp (NASDAQ:SABR) closed higher at $17.74 on Monday, in a 52-week range of $14.86 - $20.91.Click here for a free comprehensive Trend Analysis ReportTrevena Inc (NASDAQ:TRVN), a clinical stage biopharmaceutical company, posted a wider overall net loss in Q3, as research and development costs doubled. Net loss attributable to common stockholders for the quarter ended September 30, 2014 was $15.5 million, or $0.59 per share. That compares with a net loss of $8.86 million, or $11.18 a share in the prior year period. The company had 26,366,300 shares outstanding at the end of Q3 2014, compared with 793,268 in the year ago period. Trevena Inc (NASDAQ:TRVN) reported no revenue. R&D spending rose to $13 million from $6.6 million. Trevena said it expects to post top line results from a Phase 2 trial of pain treatment TRV130 in the next few weeks.Click here for a free comprehensive Trend Analysis Report
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
